Clinical Trial Search

Primary: Proportion of Subjects With Lesion Clearance — 16 Participants

Primary: The Primary Endpoint for This Study Will be a Change From Baseline in the Number of Pigmented Lesions on Skin Previously Covered by Psoriatic Plaques. — 0 participants

Primary: Maximum Tolerated Dose — 8 J/cm2

Primary: Complete Clearance Rate — 16; 15; 10; 12 AK Fields

Primary: Percentage of Grafts Successfully Treated — 78 Percentage of grafts

Primary: Number of Accumulated New Skin Lesions at Month 3 — 65; 103 new skin lesions — p=0.0120

Primary: Mean Per Subject Percentage Target Lesions Judged Clear by the Physician's Lesion Assessment (PLA) — 4.82; 26.79; 45.09 percentage of lesions cleared — p=0.0003

Primary: To Ascertain the Percentage of Surgical Site Infections Following Excision of Ulcerated Skin Tumours in Dermatology Departments. — 35 Participants

Primary: Number of Wounds by Healing Category Per Investigator Visual Assessment — 35; 5; 2; 28 wounds

Primary: Clearance of SK Lesions — 82 percentage of SK lesion clearance

Primary: Lab* Values of Lesional Area Using Dermoscopy and ImageJ — 68.850; 72.103; 73.147; 72.633 unitless

Primary: This is a Study to Measure the Efficacy of the Nd:YAG Laser to Cause Complete Regression of Basal Cell Carcinoma. — 28 tumors

Primary: Biological Tissue Response

Primary: Number of Participants With Suspicious Tumors Detected After Inspection of Problem Area and Inspection of the Full Body. — 810; 631 participants — p=<0.01

Primary: Cure Rate — 751 lesions

Primary: Number of Responders — 19 Participants

Primary: Number of Participants With Treatment-emergent Adverse Events Related to Clinical Investigation Product During the 30 Days of Follow-up — 2; 3 Participants

Primary: Mean Change From Baseline to Day 28 in PSS (Psoriasis Severity Score) of the Treatment Target Lesions Compared to Placebo Target Lesions — -1.9; -1.5 PSS score

Primary: Sensitivity and Specificity — 98.2; 9.5 Ratio * 100 — p=0.05

Primary: Psoriasis Area and Severity Index (PASI) Score — 3.9 score on a scale

Primary: Mean of Per Subject Percentages of Target Lesions Judged to be Clear (PWA=0) at Visit 8 — 3.72; 49.5; 57.88 Per-Subject Percent of Lesions Clear

Primary: Number of Participants Who Experienced an Adverse Event — 472 participants

Primary: Intra-individual Difference in Reepithelialization of Wound (Halves) at Day 14 in 'Recent Wounds' or Day 28 in 'Chronic Wounds' — 8; 0 Wounds — p==0.008

Primary: Average Scores for VLS Clinical Signs Present At Baseline, 3, 6 and 12 Months After the Last Treatment as Assessed by the Investigators — 1.85; 0.65; 0.65; 0.73 score on…

Primary: The Absence of Lentigo Maligna (LM) at the Time of Staged Excisions in Participants — 27; 29 participants

Primary: Objective Erythema Assessment Using Clinical Grading Analog Scale — 0.8; 0.83; 0.75; 0.29 score on a scale

Primary: Pigmented Lesion Improvement by Blinded Evaluation — 41 Observations

Primary: Preliminary Assessment of the Temperature of Kaposi's Sarcoma Lesions Compared to the Temperature in the Normal Skin Measured With Thermography — 1.1 Celsius

Primary: Rate of Wound Healing — 12.1; 21.3 Days

Primary: Within and Between Reader Agreement for the Measurement Techniques: Scout Length by Width, Scout Trace Area, and Scout Trace Perimeter — 20.07; 16.28; 16.28; 20.07…